Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

ty reported in almost half the patients treated with other EGFR-targeting antibody drugs in combination with radiation while absent in nimotuzumab/radiation treated patients. Reports of any severe incidents of the other side-effects that are typical of EGFR-targeting molecules have been rare. These severe side-effects can result in treatment interruptions, one of the leading causes of treatment failure and, unlike cetuximab, nimotuzumab patients do not have to be pre-medicated to prevent infusion reactions.

Nimotuzumab is being developed to compete as best-in-class therapy against the currently marketed EGFR-targeting drugs. This drug has displayed efficacy in numerous tumour types (published and presented at major conferences including ASCO), having completed more than 27 clinical trials demonstrating anti-cancer activity that rivals the other EGFR-targeting antibody drugs.

Nimotuzumab is currently being advanced in several randomized Phase II and III trials in Japan, Europe and elsewhere and is undergoing a YM-sponsored confirmatory trial in pediatric glioma in Canada and the US.

NYSE Alternext US notice

The Company received an audit opinion for the fiscal year ended June 30, 2008 which included an explanatory paragraph referencing note 1 to the consolidated financial statements of the Company's fiscal 2008 annual report which discusses substantial doubt about the Company's ability to continue as a going concern as the Company has no net earnings, minimal revenue and negative operating cash flows. YM had net cash of more than CDN $52 million at September 30, 2008 which it believes is sufficient to continue its development activity well beyond the 2009 fiscal year. The disclosure in note 1 is consistent with YM's disclosure in previous financial reports and is intended to alert readers to the risks inherent to the industry in which it operates, which include the reliance on the capital markets and uncert
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... New York , July 31, 2014 ... Global and China Insulin Market (Rapid-Acting, Short-Acting, ... Industry Analysis, Size, Share, Growth, Trends and Forecast (Value ... Forecasts Research Report. Diabetes, growing at an ... The disease has emerged as a major cause of ...
(Date:7/30/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today ... June 28, 2014. Third Quarter Financial Highlights ... $632.6 million, reflecting operational growth of 0.5% and a ... period in the prior year. , Revenues grew ... Health revenues grew 3.5%. , GYN Surgical revenues ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
Breaking Medicine Technology:The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 3The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 4The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 5The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 6The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 7The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5
... Pharmaceuticals, a division of Wyeth (NYSE: ... ongoing studies, one evaluating neratinib (HKI-272) in combination ... positive) breast cancer, and a separate study investigating ... (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent ...
... Conference Call at 9:00 AM ET Today CORAL ... (Nasdaq: CPRX ) today announced top-line results ... cocaine addiction. The data from the trial showed ... primary endpoint -- that a significantly larger proportion of ...
Cached Medicine Technology:New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 2New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 3New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 4New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer 5Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 2Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 3Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 4
(Date:7/31/2014)... With a busy lifestyle, it is hard to ... healthy lifestyle but to ensure their mental health is equally in ... health. “Eating right is key to your body’s health. However, I ... a completely healthy lifestyle,” expressed Chef Ravi, owner of World Gardens ... here . , ", 1. Stop eating lunch at your desk ...
(Date:7/31/2014)... CITY, Mo. (PRWEB) July 31, 2014 ... of highly experienced, sub-specialty trained neurosurgeons at the ... of the Spine Program and director of spine surgery. ... in Richland, Wash. , “Dr. Upadhyaya has been recognized ... invasive and complex spine issues. His addition to the ...
(Date:7/31/2014)... Hills, CA (PRWEB) July 31, 2014 According ... George W. Bush recently underwent partial knee replacement surgery on ... knee less than two months earlier. The story also reports ... the procedures and hopes to be back on the bike ... surgery highlights the benefits of partial knee replacement. , ...
(Date:7/31/2014)... WA (PRWEB) July 31, 2014 ... family practice provider? Community Health Center of Snohomish ... “ Pediatricians vs. Family Doctors ”. Many adults ... are available to them. Community Health Center hopes ... similarities and differences between the two. , ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Recognizing ... International Plant-based Nutrition Healthcare Conference announced today ... enrolled in studies of medicine or a healthcare-related field, ... advantage of special student-only discounts for the conference, scheduled ... the Loews Coronado Bay Resort. , “As ...
Breaking Medicine News(10 mins):Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 2Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 3Health News:World Garden’s Cafe Launches ‘16 Simple Ways to Feel Connected to the World’ 4Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:George W. Bush’s Surgery Highlights the Benefits of Partial Knee Replacement 2Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3
... CITY, Calif., Sept. 30 Genomic Health, Inc. ... Health,s Chief Operating Officer and Chief Financial Officer, will present ... City, on Tuesday, October 6 at 9:30 a.m. ET. ... the presentation, visit the Investor Relations section of Genomic Health,s ...
... October is National Breast Cancer Awareness Month and Topcor is ... , Available October 5th, "Clipa for a Cure" is a ... Topcor will donate 10% of the retail price of every ... American Cancer Society, breast cancer is the second leading cause ...
... ... that they now help physicians find jobs on Twitter by using the popular social ... providers. , ... CO (PRWEB) September 29, 2009 -- Onyx M.D., a Denver, Colorado-based physician recruiting company, ...
... ... live. Everyone, including doctors, administrators, nurses, et al, are encouraged to go online to ... ... first multi-disciplinary, online healthcare community. It is designed for everyone in the medical field ...
... The American Federation of Government Employees expresses grave concern at the ... would be rising by an average of 8.8% in 2010. ... for 60% of the enrollees in FEHBP, those covered by Blue ... by 15% for self coverage and 12% for family coverage. ...
... PARSIPPANY, N.J., Sept. 30 Thousands of bacteria lurk ... hygiene routines to help protect themselves from serious illness, ... College Center for Hygiene and Health in Home and ... products.(1) Despite growing concerns about influenza A (H1N1) on ...
Cached Medicine News:Health News:'Clipa for a Cure': New Pink Instant Handbag Hanger Benefits Breast Cancer Research 2Health News:Onyx M.D. Now Tweet Jobs for Physician Job Opportunities by Specialty 2Health News:Onyx M.D. Now Tweet Jobs for Physician Job Opportunities by Specialty 3Health News:Online Healthcare Community, TogetherMD, is Live 2Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 2Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 3Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 4Health News:Study Shows College Students Are Not Following CDC Recommendations to Help Protect Themselves from H1N1 and Other Threatening Germs 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: